Individuals with schizophrenia display substantial deficits in neurocognition, resulting in poor daily functioning and disability. Recent reports have suggested that neurocognitive dysfunction in this population is linked to increased inflammation. However, there is paucity of evidence supporting this link, as well as lack of information about the putative link of inflammation to daily functioning. We examined neurocognition (MCCB) and daily functioning (SLOF), as well as inflammatory markers (TNF-α, IL-6, IL-1β, and IL-12p70) in 41 individuals with schizophrenia. Poor neurocognition was significantly associated with increased peripheral TNF-α and IL-12p70 (r = −0.44 and r = −0.38, respectively, controlling for BMI, depression and antipsychotic medication). Notably, difficulties with daily functioning were significantly associated with increased peripheral TNF-α (r = −0.51) and a trend with increased IL-12p70. Our findings support previous hypotheses linking neurocognitive impairment to increased inflammation in individuals with schizophrenia. Our results extend these associations in this population, linking inflammation to poor daily functioning in this population.
Introduction
Individuals with schizophrenia have a broad range of neurocognitive deficits that contribute to poor functioning and disability (Keefe et al., 2006) . However, the exact cause underlying these deficits remains obscure. Several reports have proposed that inflammation may play a role in neurocognitive dysfunction in schizophrenia, as systemic inflammation causes microglia to release inflammatory cytokines, which bind to receptors on neurons leading to changes in mood, cognition and behavior (Khandaker et al., 2015) . Furthermore, increased inflammatory cytokines are inversely correlated with cognition (Hope et al., 2015) . Consistent with these reports, a meta-analysis of 40 studies of individuals with schizophrenia showed substantial cytokine elevations with IL-12, IFN-γ, TNF-α, soluble IL-2R (Goldsmith et al., 2016; Misiak et al., 2017) and IL-6 (Goldsmith et al., 2016; Miller et al., 2011) were elevated compared to non-clinical controls.
While extensive literature indicates that individuals with schizophrenia display substantial neurocognitive deficits and have increased inflammatory cytokines, there is paucity of evidence supporting this putative link. Furthermore, there is lack of information about whether this link impacts daily functioning in individuals with schizophrenia. While the CNS is distinct from the peripheral circulation due to the blood brain barrier, systemic cytokines do reach the CNS under normal physiologic conditions (Banks, 2005) . Thus, peripheral cytokines may provide information about the inflammatory state of the CNS.
To address these gaps in the literature, our aims are to: 1) confirm the link of altered inflammation to neurocognitive deficits in individuals with schizophrenia; and 2) examine the association between inflammation and daily functioning in this population.
Materials and methods

Participants
Data were obtained from baseline assessments of a clinical trial examining the impact of aerobic exercise on neurocognition in schizophrenia (ClinicalTrials.gov Identifier NCT01897064). The study was approved by the institutional review board and all participants provided written informed consent. The data were collected between 05/ 2012 and 07/2014.
Forty-one non-acute individuals with schizophrenia were recruited from outpatient mental health clinics in the greater NYC area. The inclusion criteria were a DSM-IV diagnosis of schizophrenia or related disorders; age 18-55 years; English-speaking; taking antipsychotic medication for at least 8 weeks and on current doses for 4 weeks and/or injectable depot antipsychotics with no change in the last 3 months; and https://doi.org/10.1016/j.bbi.2018.09.016 Received 12 April 2018; Received in revised form 8 August 2018; Accepted 11 September 2018
